Efficacy of Intramuscular ABP-450 (prabotulinumtoxinA) Injection for the Treatment of Cervical Dystonia (Protocol No. ABP-19000)

Clinical Trial Title

A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Intramuscular ABP-450 (prabotulinumtoxinA) Injection for the Treatment of Cervical Dystonia (Protocol No. ABP-19000)

National Clinical Trial Number:

NCT04849988

Contact Information

Clinical Trial Protocol Description:

The purpose of this study is to determine whether an investigational drug, ABP-450 (prabotulinumtoxinA) is safe and effective in treating cervical dystonia (CD), compared with placebo (a non-active formula).

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Be between the ages of 18 and 75 years old
  • A clinical diagnosis of cervical dystonia
  • On stable medications for 3 months

You will be excluded from the study if:

  • You have traumatic or tardive torticollis
  • Denervation surgery in the affected muscles
  • Hypersensitivity to botulinum toxin type A

This is a partial list of inclusion and exclusion criteria.

Study Details

Clinical Trial Investigator

Katie Kompoliti, MD

Contact Information

Olga Solonowicz

Clinical Trial Location

Rush University Medical Center

Location

Rush University Medical Center

1620 W Harrison St
Chicago, IL 60612

Get Directions

Clinical Trial FAQs

Find out if a clinical trial makes sense for you.

Learn more
Learn more